Immunogenicity of the Two mRNA SARS-CoV-2 Vaccines in a Large Cohort of Dialysis Patients

Paraskevi Tsoutsoura; Efstathios Xagas; Kyriaki Kolovou; Polyxeni Gourzi; Sotirios Roussos; Angelos Hatzakis; Ioannis N. Boletis; Smaragdi Marinaki

doi:10.3390/idr14060093

Infectious Disease Reports (Nov 2022)

Immunogenicity of the Two mRNA SARS-CoV-2 Vaccines in a Large Cohort of Dialysis Patients

Paraskevi Tsoutsoura,
Efstathios Xagas,
Kyriaki Kolovou,
Polyxeni Gourzi,
Sotirios Roussos,
Angelos Hatzakis,
Ioannis N. Boletis,
Smaragdi Marinaki

Affiliations

Paraskevi Tsoutsoura: Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, Medical School of Athens, National and Kapodistrian University, 11527 Athens, Greece
Efstathios Xagas: Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, Medical School of Athens, National and Kapodistrian University, 11527 Athens, Greece
Kyriaki Kolovou: Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, Medical School of Athens, National and Kapodistrian University, 11527 Athens, Greece
Polyxeni Gourzi: Molecular Immunopathology and Histocompatibility Unit, Onassis Cardiac Surgery Center, 17674 Athens, Greece
Sotirios Roussos: Department of Hygiene, Epidemiology & Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, Greece
Angelos Hatzakis: Department of Hygiene, Epidemiology & Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 15772 Athens, Greece
Ioannis N. Boletis: Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, Medical School of Athens, National and Kapodistrian University, 11527 Athens, Greece
Smaragdi Marinaki: Clinic of Nephrology and Renal Transplantation, Laiko General Hospital, Medical School of Athens, National and Kapodistrian University, 11527 Athens, Greece

DOI: https://doi.org/10.3390/idr14060093
Journal volume & issue: Vol. 14, no. 6
pp. 946 – 954

Abstract

Read online

Chronic kidney disease patients, especially those on hemodialysis, are at the highest risk of a severe course and death from COVID-19. Moreover, they appear to have suboptimal response in both cellular and humoral immunity after vaccination. The present study investigated humoral and cellular response and safety after two doses of either of the two authorized mRNA vaccines in a cohort of 310 patients on maintenance dialysis. The antibody response rate was 94.5%, with a median (25th, 75th) antibody titer of 3478 (1236, 8141) AU/mL. Only mild adverse effects were observed. Only vaccine type was independently associated with immunogenicity. Α statistically significant difference in favor of mRNA1273 versus BNT162b2 vaccine was observed. Antibody positivity (100% vs. 94.3%, p p p < 0.001). Both mRNA vaccines are safe for dialysis patients and can trigger humoral and cellular responses, although with lower titers than those that have been reported to healthy individuals.

Published in Infectious Disease Reports

ISSN: 2036-7430 (Print); 2036-7449 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Other systems of medicine
Website: https://www.mdpi.com/journal/idr

About the journal

Abstract

Keywords